Safety of tucatinib triplet for HER2+ breast cancer sealed in real-world analysis

Real-world data from a retrospective, single-center, cohort study—presented during the 2022 San Antonio Breast Cancer Symposium—of patients with HER2-positive metastatic breast cancer who received tucatinib, trastuzumab, and capecitabine confirmed the safety profile of the triplet therapy regimen from the HER2CLIMB trial.